Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $8.68 Million - $10.1 Million
161,900 Added 1264.84%
174,700 $10.9 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $4.04 Million - $4.73 Million
-68,200 Reduced 84.2%
12,800 $757,000
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $7.69 Million - $8.37 Million
-124,200 Reduced 60.53%
81,000 $5.41 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $11.1 Million - $12.5 Million
187,500 Added 1059.32%
205,200 $13 Million
Q4 2020

Feb 16, 2021

SELL
$57.74 - $65.43 $4.15 Million - $4.7 Million
-71,900 Reduced 80.25%
17,700 $1.1 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $10.4 Million - $11.6 Million
-181,900 Reduced 67.0%
89,600 $5.4 Million
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $9.57 Million - $13.9 Million
206,200 Added 315.77%
271,500 $15.1 Million
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $6.15 Million - $8.02 Million
-125,000 Reduced 65.69%
65,300 $4.19 Million
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $6.18 Million - $7.33 Million
144,500 Added 315.5%
190,300 $9.65 Million
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $1.2 Million - $1.33 Million
26,900 Added 142.33%
45,800 $2.08 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $108,288 - $129,120
2,400 Added 14.55%
18,900 $902,000
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $7.04 Million - $7.94 Million
-127,600 Reduced 88.55%
16,500 $1.02 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $3.98 Million - $4.96 Million
78,700 Added 120.34%
144,100 $7.97 Million
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $3.92 Million - $4.51 Million
65,400 New
65,400 $4.14 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $88.3B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.